Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
Total Valuation
Amylyx Pharmaceuticals Inc has a market cap or net worth of $450.16M. The enterprise value is ―.
Market Cap$450.16M
Enterprise Value―
Share Statistics
Amylyx Pharmaceuticals Inc has 89,141,090 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding89,141,090
Owned by Insiders9.33%
Owned by Institutions46.80%
Financial Efficiency
Amylyx Pharmaceuticals Inc’s return on equity (ROE) is -1.83 and return on invested capital (ROIC) is -188.50%.
Return on Equity (ROE)-1.83
Return on Assets (ROA)-1.56
Return on Invested Capital (ROIC)-188.50%
Return on Capital Employed (ROCE)-1.90
Revenue Per Employee710.33K
Profits Per Employee-2.45M
Employee Count123
Asset Turnover0.45
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Amylyx Pharmaceuticals Inc is -0.85. Amylyx Pharmaceuticals Inc’s PEG ratio is 0.05.
PE Ratio-0.85
PS Ratio0.00
PB Ratio1.45
Price to Fair Value1.56
Price to FCF-1.84
Price to Operating Cash Flow-1.43
PEG Ratio0.05
Income Statement
In the last 12 months, Amylyx Pharmaceuticals Inc had revenue of 87.37M and earned -301.74M in profits. Earnings per share was -4.43.
Revenue87.37M
Gross Profit45.22M
Operating Income-314.73M
Pretax Income-302.14M
Net Income-301.74M
EBITDA-290.98M
Earnings Per Share (EPS)-4.43
Cash Flow
In the last 12 months, operating cash flow was -167.65M and capital expenditures -157.00K, giving a free cash flow of -167.80M billion.
Operating Cash Flow-167.65M
Free Cash Flow-167.80M
Free Cash Flow per Share-1.88
Dividends & Yields
Amylyx Pharmaceuticals Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change202.84%
50-Day Moving Average4.54
200-Day Moving Average4.03
Relative Strength Index (RSI)59.02
Average Volume (3m)964.35K
Important Dates
Amylyx Pharmaceuticals Inc upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Amylyx Pharmaceuticals Inc as a current ratio of 6.67, with Debt / Equity ratio of 1.20%
Current Ratio6.67
Quick Ratio6.67
Debt to Market Cap<0.01
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Amylyx Pharmaceuticals Inc has paid -393.00K in taxes.
Income Tax-393.00K
Effective Tax Rate<0.01
Enterprise Valuation
Amylyx Pharmaceuticals Inc EV to EBITDA ratio is -0.63, with an EV/FCF ratio of -1.09.
EV to Sales2.08
EV to EBITDA-0.63
EV to Free Cash Flow-1.09
EV to Operating Cash Flow-1.09
Balance Sheet
Amylyx Pharmaceuticals Inc has $176.50M in cash and marketable securities with $1.98M in debt, giving a net cash position of -$174.52M billion.
Cash & Marketable Securities$176.50M
Total Debt$1.98M
Net Cash-$174.52M
Net Cash Per Share-$1.96
Tangible Book Value Per Share$2.42
Margins
Gross margin is -43.25%, with operating margin of -360.22%, and net profit margin of -345.36%.
Gross Margin-43.25%
Operating Margin-360.22%
Pretax Margin-345.81%
Net Profit Margin-345.36%
EBITDA Margin-333.03%
EBIT Margin-334.07%
Analyst Forecast
The average price target for Amylyx Pharmaceuticals Inc is $11.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.00
Price Target Upside106.38% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-100.32%
EPS Growth Forecast-197.69%